IP Library Granted Patent US 11,890,290
Granted Patent B2
US 11,890,290 · App. 17/374,488 · Granted Feb 6, 2024

Topical treatment of wounds with statins and cholesterol for scar reduction

Inventors: Thomas A. Mustoe (Evanston, IL); Robert D. Galiano (Chicago, IL); Seok Jong Hong (Northbrook, IL); Ping Xie (Chicago, IL); Shengxian Jia (Wilmette, IL)
Assignee: Northwestern University
A61K31/575A61K9/0014A61K9/06A61K9/107A61K9/1075A61K9/14A61K31/22A61K31/225A61K31/366A61K45/06A61K47/10A61K47/12A61K47/14A61K47/44A61P17/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,890,290
App. No.
17/374,488
Granted
Feb 6, 2024
Kind
B2
Abstract

Provided herein are compositions, systems, and methods for treating wounds with the combination of statins and cholesterol to help prevent and reduce scar formation.

Claims (31)

1. A method of preventing or reducing scar formation in the skin of a subject during wound healing comprising administering a composition to a wound site of the subject, wherein the composition comprises:

i) 6-10% of a statin selected from the group consisting of simvastatin, rosuvastatin, lovastatin, cerivastatin, fluvastatin, mevastatin, pitavastatin, and pravastatin;

ii) 1-15% of:

a) cholesterol,

b) cholesterol derivative selected from the group consisting of cholesteryl capronate, cholesteryl pelargonate, cholesteryl caprinate, cholesteryl undecilate, cholesteryl laurate, cholesteryl tridecilate, cholesteryl miristinate, cholesteryl palmitate, and cholesteryl stearate, or

c) cholesterol analog selected from the group consisting of sitosterol, stigmasterol, fucosterol, spinasterol, campesterol, brassicasterol and ergosterol; and

iii) a pharmaceutically acceptable carrier.

2. A composition comprising:

i) 6-10% of a statin selected f rom the group consisting of simvastatin, rosuvastatin, lovastatin, cerivastatin, fluvastatin, mevastatin, pitavastatin, and pravastatin;

ii) 1-15% of:

a) cholesterol,

b) cholesterol derivative selected from the group consisting of cholesteryl capronate, cholesteryl pelargonate, cholesteryl caprinate, cholesteryl undecilate, cholesteryl laurate, cholesteryl tridecilate, cholesteryl miristinate, cholesteryl palmitate, and cholesteryl stearate, or

c) cholesterol analog selected from the group consisting of sitosterol, stigmasterol, fucosterol, spinasterol, campesterol, brassicasterol and ergosterol; and

iii) a pharmaceutically acceptable carrier.

3. The composition of claim 2 , wherein said composition is in a form selected from the group consisting of a powder, a spray, an ointment, a paste, a cream, a lotion and a gel.

4. The composition of claim 2 , wherein said statin is simvastatin.

5. The composition of claim 2 , wherein said cholesterol derivative is cholesteryl capronate.

6. The composition of claim 2 , wherein said cholesterol analog is sitosterol.

7. The composition of claim 2 , wherein said statin is selected from the group consisting of: rosuvastatin, lovastatin, cerivastatin, fluvastatin, mevastatin, and pitavastatin.

8. The composition of claim 2 , wherein said statin has a molecular weight of less than 500 daltons.

9. The composition of claim 2 , wherein said pharmaceutically acceptable carrier is in the form of an emulsion.

10. The composition of claim 9 , wherein said composition further comprises a surfactant.

11. The composition of claim 10 , wherein said emulsion is a microemulsion.

12. The composition of claim 9 , wherein said emulsion is an oil-in-water emulsion.

13. The composition of claim 9 , wherein said emulsion is a water-in-oil emulsion.

14. The composition of claim 9 , further comprising at least one of the following: polyethylene glycol, oleic acid, and 2-(2-ethoxyethoxy) ethanol.

15. The composition of claim 2 , wherein said cholesterol, cholesterol derivative or cholesterol analog is cholesterol.

16. The composition of claim 15 , wherein said statin is pitavastatin.

17. The composition of claim 9 , wherein said emulsion comprises a surfactant and a solvent.

18. The composition of claim 10 , wherein said surfactant is monoacylglycerols.

19. The method of claim 1 , wherein said composition is applied topically.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 7, 2023
From: NORTHWESTERN UNIVERSITY
To: UNITED STATES GOVERNMENT
Reel/Frame 062967/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2022
From: MUSTOE, THOMAS A.; GALIANO, ROBERT D; HONG, SEOK JONG; XIE, PING; JIA, SHENGXIAN
To: NORTHWESTERN UNIVERSITY
Reel/Frame 059234/0107 →
Continuity (3)
Continuation 16047464 · Jul 27, 2018
Provisional Application 62537534 · Jul 27, 2017
Related Publication 20220133743A1 · May 5, 2022